glp-1 who should not take Why do patients stop drugs? GLP-1 Weight Loss Drugs: Impact

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Out-of-pocket costs are the strongest predictor of abandonment: High OOP costs drive non-adherence, especially in obesity, where coverage is limited and stigma persists

Selected Oral Agents for Type 2 Diabetes - Januvia

GLP-1s are proving their value well beyond the scale, with benefits ranging from improved glycemic control and reduced cardiovascular risk to better mobility and quality of life

Explore efficacy, safety and dosing information for Advil Liqui-Gels, a fast-acting acute pain reliever and fever reducer with 200mg ibuprofen

Research suggests 2539% of weight lost on these medications may come from lean tissue, not fat